WO2013075199A1 - "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos - Google Patents
"compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos Download PDFInfo
- Publication number
- WO2013075199A1 WO2013075199A1 PCT/BR2012/000480 BR2012000480W WO2013075199A1 WO 2013075199 A1 WO2013075199 A1 WO 2013075199A1 BR 2012000480 W BR2012000480 W BR 2012000480W WO 2013075199 A1 WO2013075199 A1 WO 2013075199A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- och
- compounds
- compound
- cells
- Prior art date
Links
- 0 COc(cc(cc1OC)C(**=CC2=C*C=C2)=O)c1OC Chemical compound COc(cc(cc1OC)C(**=CC2=C*C=C2)=O)c1OC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
Definitions
- the present invention relates to 3,4,5-trimethoxyphenylhydrazide-derived acylhydrazones for the treatment of diseases associated with cell proliferation (such as leukemias, tumors, inflammation and other proliferative diseases). More specifically, the invention relates to compounds having cyclin-dependent protein kinase (CDKs) and topoisomerase I inhibitory activity, which may therefore be useful in the treatment of acute lymphoid leukemia (ALL). The invention further relates to obtaining unpublished acylhydrazones and oxadiazoles from 3,4,5-trimethoxyphenylhydrazide.
- CDKs cyclin-dependent protein kinase
- ALL acute lymphoid leukemia
- Neoplastic cells differ from normal cells by their high invasive power, loss of function, loss of differentiation, and metastasis because they have less adhesion to each other (Rang, HP; Dale, MM; Ritter, J. M. Moore, PK Pharmacology 5th ed Rio de Janeiro: Elsevier, 2004. 703 p).
- Leukemias are one of several types of cancer, and occur by neoplastic proliferation of lymphoid or myeloid hematopoietic cells, resulting from the mutation of a single stem cell whose offspring forms a clone of leukemic cells.
- leukemias are one of several types of cancer, and occur by neoplastic proliferation of lymphoid or myeloid hematopoietic cells, resulting from the mutation of a single stem cell whose offspring forms a clone of leukemic cells.
- several genetic changes occur for malignant transformation, including inadequate expression of oncogenes and loss of function of tumor suppressor genes (Bain, BJ Diagnosis in Leukemia. Rio de Janeiro: Elsevier, 2003, Chap. 1, 01-56), which may be associated with genetic or risk factors (such as smoking, radiation exposure or chemicals such as benzene) (INCA, National Cancer Institute.
- Leukemia - prevention, genetics, other risk factors available at:
- Acute leukemias are characterized by a defect in cell maturation, which causes an imbalance between proliferation and maturation; as leukemic clone cells continue to proliferate without reaching maturation and death, leading to continued expansion of the leukemic clone and predominance of immature cells (INCA 2009b, Bain, BJ Leukemia diagnosis. Rio de Janeiro: Elsevier , 2003, Chap. 1, 01-56).
- Acute lymphoid leukemia is due to the uncontrolled proliferation of immature lymphoid progenitor cells in the bone marrow, which results in very rapid accumulation of neoplastic cells (Plasschaert, S .; Van Der Kolk, D .; De Bont, E .; Vellenga, E., Kamps, W .; De Vries, E. Breast Cancer Resistance Protein (BCRP) in Acute Leukemia. Leukemia & Lymphoma, 2004, 45, 649-654).
- ALL Acute lymphoid leukemia
- Taxol TM paclitaxel antineoplastic
- vincristine an alkaloid used in the therapy of acute leukemia and other tumor types, which acts in the same way as paclitaxel by binding to tubulin, interfering with microtubule formation (polymerization) or reorganization (depolymerization) (Goodman and Gilman. the pharmacological basis of therapeutics, 10th Ed., published by the McGraw-Hill Companies. 2006).
- the most commonly used chemotherapy drugs in current leukemia therapy include daunorubicin, doxorubicin, dexamethasone, vincristine, methotrexate and mercaptopurine (Plasschaert, S .; Van Der Kolk, D .; De Bont, E .; Kell, W .; De Vries, E. Breast Cancer Resistance Protein (BCRP) in Acute Leukemia (Leukemia & Lymphoma, 2004, 45, 649-654). These drugs confer therapeutic benefit but also significant toxicity to the organism and normal cells due to their role in inducing apoptosis and inhibiting cell proliferation (Herr, I.; Debatin, KM; Cellular stress response and apoptosis in cancer therapy.
- BCRP Breast Cancer Resistance Protein
- Antineoplastic agents also interfere with normal tissues that have rapidly dividing cells and can cause many undesirable effects, such as reduced production of the body's defense cells, poor wound healing, alopecia, gastrointestinal epithelium damage, sterility and teratogenicity ( Rang, HP; Dale, MM; Ritter, J. M.; Moore, PK Pharmacology. 5th ed. Rio de Janeiro: Elsevier, 2004. 703 p).
- results in murine cells B16F1 and A375 (in vitro) of these compounds showed no improvement in potency and selectivity of the starting compound, these results were very promising and identified some important structural components for anti-melanoma activity (Wang, Z Lu, Y; Seibel, W.; Miller, DD; Li, W. Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening. Journal of Chemical Informati 1420-1427).
- acylhydrazones appear as an interesting class of compounds with antitumor activity.
- the present invention relates to the production of acylhydrazones, especially derivatives of 3,4,5-trimethoxyphenylhydrazide, for the treatment of cell proliferation associated diseases (such as leukemias, tumors, inflammation and other proliferative diseases).
- Patent application PI 0112674-1 (Cyclin-dependent kinases n- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors) describes compounds and their pharmaceutically acceptable enantiomorphs, diastereoisomers, solvates and salts as protein kinase inhibitors useful in the treatment of proliferative diseases such as cancer, inflammation and arthritis.
- the synthesized compounds may also be useful for the treatment of Alzheimer's disease, chemotherapy-induced alopecia and cardiovascular disease.
- the compounds described in PI 0112674-1 represent more complex structures than those disclosed throughout the present invention.
- the compounds referenced in US Patent Application Publication No. 20040138272 (1,4-Substituted cyclohexane derivatives) may be useful in preventing cell proliferation in malignant diseases by inhibiting Rho kinases useful in inducing central and peripheral nervous system repair by induction. of axon growth and regeneration.
- the mechanism of action of the compounds of US 20040138272 differs from that proposed for the structures of the present invention.
- Cyclin-dependent kinase inhibitors useful in modulating cell cycle progression are proposed in patent application PI 0418095-0 (Cyclin-dependent kinase inhibitors, compositions and uses related thereto). Such compounds would be useful for treating patients with disorders associated with excessive cell proliferation.
- the compounds described in PI 0418095-0 are different acylhydrazones from those proposed during the present invention, with a more complex synthesis process.
- Patent application PI 0508364-8 (4-Benzimidazol-2-yl-pyridazin-3-one derivatives) describes compounds and their physiologically tolerated salts which act as kinase inhibitors, in particular CDK2 kinase 2 cyclin-dependent).
- the compounds of PI 0508364-8 are different from those proposed throughout the present invention with more complex synthesis.
- U.S. Patent Application Publication No. 20070066610 (Acylhydrazones as kinase modulators) describes acylhydrazones as inhibitors of tyrosine kinases, comprising c-et, a receptor tyrosine kinase that regulates cell proliferation, morphogenesis and motility.
- the acylhydrazones described in US 20070066610 differ from those proposed in the course of this invention with more complex synthesis. Furthermore, the target action of the described compounds differs from that proposed in this invention.
- US Patent Application Publication 20080194562 (Pyrazole Derivatives for the Inhibition of Cdk's and Gsk's) refers to the synthesis of pyrazoles, compounds which inhibit or modulate the activity of cyclin-dependent kinases (CDK) and glycogen synthase kinases (GSK), and their use in the treatment or prophylaxis of kinase-mediated disease or condition. Also disclosed are pharmaceutical compositions containing the chemical compounds and intermediates. The compounds of US 20080194562 are different from those proposed in the course of the present invention.
- Oxadiazoles are an important class of heterocyclic compounds with a wide range of biological activities such as antiviral, antimicrobial, antineoplastic, fungicidal, tyrosinase inhibition and cathepsin K (Kumar, D .; Sundaree, S.; Johnson, EO; Shah, K. An efficient synthesis and biological study of novel indolyl-1,3,4-oxadiazoles as potent anticancer agents.
- Bioorganic & Medicinal Chemistry Letters, 2009, 19, 4492-4494 are excellent amide and ester bioisters that can contribute substantially to increased pharmacological activity by participating in hydrogen bonds as receptors (Guimar ⁇ es, CRW; Boger, D.L; Jorgensen, W.L Elucidation of Fatty Acid Amide Hydrolase Inhibition by Potent ⁇ -Ketoheterocycle Derivatives from Monte Carlo Simulations, Journal of the American Chemical Society, 2005, 127, 17377-17384).
- the aim of the present invention is to obtain synthetic compounds derived from 3,4,5-trimethoxyphenylhydrazide (hydrazones and oxadiazols) and all analogues and the like thereof by simple synthetic route as well as the use of these compounds.
- synthetic compounds derived from 3,4,5-trimethoxyphenylhydrazide (hydrazones and oxadiazols) and all analogues and the like thereof by simple synthetic route as well as the use of these compounds.
- diseases associated with cell proliferation such as leukemias, especially acute lymphoid leukemia - ALL
- the present invention also describes the processes used for determining the biological activity of these compounds.
- the present invention relates to a class of acylhydrazones, especially those derived from 3,4,5-trimethoxyphenylhydrazide, as well as their oxadiazole analogous compounds and other analogous and similar compounds, and the pharmaceutical application of all of these in the present invention.
- treatment of different diseases associated with cell proliferation such as leukemias, including acute lymphoid leukemia (ALL), tumors and inflammation.
- ALL acute lymphoid leukemia
- the present invention also describes the methods used for determining the biological activity of all such compounds.
- acylhydrazones with activity similar to the compound used as standard in the experiments (colchicine) were obtained.
- the higher selectivity of the compounds presented in this invention is an important feature related to lower side effects than the drugs currently employed in the clinic.
- Synthesized acylhydrazones, more specifically compounds 02 and 07 showed important antileukemic activity, indicating 02 and 07 as candidates for prototype drugs, or drugs, for the treatment of leukemia, especially acute lymphoid leukemia (ALL), tumors. and other proliferative diseases such as inflammation.
- ALL acute lymphoid leukemia
- the mechanism of action of the most active compounds was determined by the use of DNA microarrays and subsequent tests indicated by the chip, as well as selectivity studies in healthy human lymphocytes.
- Figure 2 shows that Compound 07 induces cell cycle arrest in G2 / M.
- Jurkat cells treated for 18 h with 125 nM of compound 07 or DMSO were subjected to cell cycle analysis after propidium iodide labeling and flow cytometry analysis.
- Figure 3 shows results of Western blot analysis for various cell cycle regulators. Protein extracts from Jurkat cells treated with 125 nM of compound 07 (F8) or vehicle (DMSO).
- Figure 4 shows that compound 07 is a strong apoptosis inducer in Jurkat cells. Taken together, the results suggest that compound 07 promotes cell cycle arrest and apoptosis mainly through Chk2 and Rb.
- Jurkat cells treated for 18h with 125 nM of compound 07 or DMSO were double-labeled with annexin V / propidium iodide and analyzed by flow cytometry.
- FIG 5 shows the effect of compound 07 on human lymphocytes (WBC) and 15 Jurkat and REH leukemic cells after 48h. Normal lymphocyte proliferation was stimulated with phytohemagglutinin. The percent survival value of the compound 07 treated cells relative to the survival of the same vehicle treated cells (DMSO) is shown.
- the present invention comprises the obtainment and mechanism of action of synthetic acylhydrazones and their analogous compounds and the like, which may be useful in the treatment of leukemias, especially acute lymphoid leukemia (ALL), tumors and other proliferative diseases, such as inflammation.
- ALL acute lymphoid leukemia
- ring B represents:
- a complementary group of compounds according to the present invention comprises compounds of structure II:
- ring B represents:
- ring B represents:
- novel acylhydrazones of the present invention were obtained from the condensation reaction between 3,4,5-trimethoxyphenylhydrazide and different aldehydes using refluxing ethanol as the reaction as follows: wherein ring B represents:
- Table 1 shows the yields obtained in the syntheses and experimental melting points of unpublished 3,4,5-trimethoxyphenylhydrazones.
- compound 02 was previously published as a reaction intermediate to obtain oxadiazoles (azzone, G .; Bonina, F .; Formica, F. Some aroylhydrazones of halobenzaldehydes and halo-substituted 2,5-diaryl-, 3,4- Pharmaco, Ediette Scientifica, 1978, 33 (12), 963-71) and compound 07 has previously been evaluated as a MAO (monoamine oxidase) inhibitor (Mazzone, G .; Arrigo Reina, R.
- MAO monoamine oxidase
- ring B represents:
- ring B represents:
- Table 2 shows the yields obtained in the syntheses and the experimental melting point of oxadiazoles.
- the present invention also describes the determination of the mechanism of action of synthesized acylhydrazones and their analogous and similar compounds comprising oxadiazoles.
- the invention further relates to the use of all these compounds as prototypes of drugs, or drugs, for the treatment of
- ALL acute lymphoid leukemia
- tumors and other diseases associated with cell proliferation, such as inflammation.
- ALL acute lymphoid leukemia
- acylhydrazones described in the present invention selectively act on nanomolar-active leukemic cells as compared to their activity in healthy human lymphocytes, as will be described below in
- the present invention describes pharmaceutical compositions comprising compounds described above in association with pharmaceutically acceptable excipients, vehicles and adjuvants.
- pharmaceutically acceptable means a non-toxic, inert solid, semi-solid liquid excipient, diluent, auxiliary formulation of any kind, or simply a sterile aqueous medium such as saline.
- materials that may serve as pharmaceutically acceptable carriers are sugars such as lactose,
- glucose and sucrose starches such as cornstarch and potato starch, cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate, cyclodextrin; oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol, polyols such as glycerin glycol, sorbitol, mannitol and polyethylene; esters such as ethyl laurate, ethyl oleate, agar; buffering agents such as aluminum hydroxide and magnesium hydroxide; alginic acid; pyrogen free water; isotonic saline, Ringer's solution; ethyl alcohol and phosphate buffer solutions as well as other compatible non-toxic substances used in pharmaceutical formulations.
- starches such as cornstarch and potato starch, cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose and cellulose
- compositions comprising the compounds of the present invention may be for administration in any type of administration, especially parenteral administration.
- compositions of the present invention may comprise any type of excipient used in the manufacture of medicaments in any of the above mentioned pharmaceutical forms, such as absorbents, diluents, binders, disintegrants, lubricants, glidants, plasticizers, coating agents, matrix forming agents. controlled release solvents and co-solvents, wetting agents, emulsifying agents, surfactants, consistency donating agent, tonicity agents, wetting agents, airborne blowing agents, alkalizing or acidifying agents, preservatives, antioxidants, bactericides, bacteriostats, chelating, coloring and sweetening agents.
- excipient used in the manufacture of medicaments in any of the above mentioned pharmaceutical forms
- absorbents such as absorbents, diluents, binders, disintegrants, lubricants, glidants, plasticizers, coating agents, matrix forming agents. controlled release solvents and co-solvents, wetting agents, emulsifying agents, surfactants, consistency donating
- Suitable absorbers for the compositions of the present invention may be any substance added to absorb water present in the extracts or to fix certain volatile compounds, such as essences.
- Non-limiting examples of such excipients are calcium phosphate, kaolin, magnesium carbonate, bentonite and talc.
- compositions of the present invention may comprise, as a diluent, any inert product added to the formula to enable tablets or capsules to be filled with adequate volumes and to provide flow and compression properties necessary for production, for example, but not limited to. lactose, tribasic calcium phosphate, starch, mannitol, calcium sulfate, microcrystalline cellulose (MicrocelD, AvicelD), dibasic calcium phosphate (EncompressD, Ditabn), magnesium oxide, magnesium carbonate, talc, kaolin, calcium carbonate, dextrose , fructose, lactose, aspartame, cellulose, maltose, mannitol, guar gum, sorbitol, starch and sucrose.
- lactose tribasic calcium phosphate
- starch mannitol
- mannitol calcium sulfate
- microcrystalline cellulose MicrocelD, AvicelD
- dibasic calcium phosphate EncompressD, Ditab
- Suitable binder substances for the compositions of the present invention may be agents used to promote particle adhesion during granulation and compression of solid dosage forms, they may also be used in the compositions of the present invention, for example carbopol, povidone, xanthan gum, gum arabic. , alginic acid, compressible sugar, C-Na, ethylcellulose, gelatin, methylcellulose, povidone (PVP), starch, pregelatinized starch and liquid glucose in solution, dispersion or powder form.
- Suitable disintegrants or disintegrants for the compositions of the present invention may be any component employed to accelerate disintegration and / or dissolution of the pharmaceutical form in biological fluids, for example alginic acid, starch, sodium alginate, CMC-Na, microcrystalline cellulose, croscarmellose sodium (Ac-Di-SolD), starch sodium glycolate (ExplotabD) and crospovidone (Kollidon CLD).
- alginic acid starch, sodium alginate, CMC-Na, microcrystalline cellulose, croscarmellose sodium (Ac-Di-SolD), starch sodium glycolate (ExplotabD) and crospovidone (Kollidon CLD).
- Suitable lubricants for the compositions of the present invention may be, for example, magnesium stearate, calcium stearate, stearic acid, talc and hydrogenated vegetable oil (eg LubritabD).
- Suitable glidants for the compositions of the present invention may be, for example, colloidal silica (Aerosil 200D) and talc.
- Plasticizing agents suitable for the compositions of the present invention may be used in conjunction with polymers to modify their phase transition temperature and to facilitate the coalescence of films formed on granules, tablets or pellets.
- Nonlimiting examples of such agents are glycerine, triethylcitrate, dibutylphthalate, silicone and PPG.
- Coating agents employed to coat compositions of the present invention in the form of tablets, granules, capsules or pellets may be, for example, cellulose acetophthalate, ethylcellulose, gellan gum, maltodextrin, methacrylates, methylcellulose, microcrystalline cellulose, shellac, waxes, shellacs, gelatin, cellulose derivatives (methyl or ethylcellulose, cellulose acetophthalate, hydroxypropyl methylcellulose, cellulose acetate), copolymers of acrylic and methacrylic esters (EudragitD types L100, RS 30D, RS PM, S100, among others), polyvinyl alcohol (PVA) and polyvinyl acetate.
- PVA polyvinyl alcohol
- Controlled release matrix forming agents possibly employed in the compositions of the present invention for the purpose of obtaining prolonged and / or controlled release of the active ingredient (s) may be HPMC, CMC-Na, xanthan gum, CarbopolD, various types of EudragitD, agar, PEOs, cyclodextrin, nanospheres and nanoparticles. any nature.
- Solvents and co-solvents such as alcohol, corn oil, cottonseed oil, glycerin, isopropyl alcohol, mineral oil, oleic acid, peanut oil, purified water and water for injection, among others, may also be used in the present compositions. invention.
- Suitable wetting agents for the compositions of the present invention may be any substance added for the purpose of decreasing surface tension at the solid / liquid interface, for example sodium lauryl sulfate (LSS), sodium docusate and polysorbates 20, 60, 80 (Tween 20, 60, 80).
- LSS lauryl sulfate
- Tween 20, 60, 80 Teween 20, 60, 80
- Suitable emulsifying agents for the compositions of the present invention may be, for example, glyceryl monostearate, cetyl alcohol and gelatin and auxiliaries such as CMC-Na, MC, alginate and pectin.
- Surfactants such as benzalkonium chloride, nonoxynol 10, octoxynol 9, polysorbate 80 and sodium lauryl sulfate are also suitable for the compositions of the present invention.
- Consistency donors suitable for the compositions of the present invention may be any substance used to increase the consistency of ointments, for example cetyl alcohol, white wax, yellow wax, stearyl alcohol, paraffin, microcrystalline wax and cetyl ester wax.
- Suitable tonicity agents for the compositions of the present invention may be any substance used to obtain solutions with osmotic characteristics similar to those of biological fluids for ocular, nasal, parenteral administration such as NaCl (0.9%), mannitol (5). , 07%) and dextrose (5.51%).
- Suitable humectants for the compositions of the present invention may be glycerine, propylene glycol and sorbitol.
- Suitable lifting agents for the compositions of the present invention may be any liquid used as a facilitating agent in the process of reducing drug particles during the preparation of emulsions, oily bases, among others, for example mineral oil (liquid petroleum jelly), glycerin, propylene glycol , PEG 400, cottonseed oil, castor oil and Polysorbate 80 (Tween ® 80).
- Air release agents suitable for the compositions herein may be employed to expel air from hermetically sealed containers or fluid formulations to increase stability, for example nitrogen (N2) and carbon dioxide (CO2).
- N2 nitrogen
- CO2 carbon dioxide
- Alkalizing or acidifying agents such as citric acid, ammonia solution, acetic acid, ammonium carbonate, fumaric acid, diethanolamine, hydrochloric acid (HCI), monoethanolamine, tartaric acid, potassium hydroxide (KOH), boric acid, sodium hydroxide ( NaOH), sodium bicarbonate, sodium borate and triethanolamine are also suitable for the compositions of the present invention.
- Preservatives that may be used in the compositions of the present invention are, for example, antifungals such as benzoic acid, sodium benzoate, butylparaben, methylparaben (Nipagin), propylparaben (Nipasol), ethylparaben, sodium propionate, and antibacterials such as benzalkonium chloride. , benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol and phenol.
- antifungals such as benzoic acid, sodium benzoate, butylparaben, methylparaben (Nipagin), propylparaben (Nipasol), ethylparaben, sodium propionate
- antibacterials such as benzalkonium chloride.
- benzethonium chloride benzyl alcohol
- cetylpyridinium chloride chlorobutanol and phenol.
- Suitable antioxidant agents for the compositions of the present invention may be selected from the group comprising butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), ⁇ -tocopherol, ascorbic acid, sodium metabisulfite, ethylenediamine tetraacetic acid (EDTA), citric acid, cysteine, glutathione vitamin C, sodium metabisulphite, cysteine and sodium thiosulphate.
- BHA butylhydroxyanisole
- BHT butylhydroxytoluene
- ⁇ -tocopherol ascorbic acid
- sodium metabisulfite sodium metabisulfite
- EDTA ethylenediamine tetraacetic acid
- citric acid cysteine
- glutathione vitamin C glutathione vitamin C
- sodium metabisulphite cysteine and sodium thiosulphate
- compositions of the present invention may further comprise, as buffering agents, citrate buffer, phosphate buffer and borate buffer.
- colorants flavorings and flavorings can be used, for example, vanilla, menthol, cinnamon oil, anise oil and cocoa.
- Sweeteners may be, for example, aspartame, dextrose (glucose), mannitol, sorbitol, saccharin, sodium cyclamate, sugar, potassium acesulfame, sucralose and stevioside.
- compositions of the present invention may further comprise excipients such as bactericides, bacteriostats, antioxidants, preservatives, buffers, stabilizers, pH adjusters, osmolarity adjusters, antifoam and surfactants, and residues of antigen inactivating or fractionating agents, growth media and solvents commonly used in the production of medicines.
- excipients such as bactericides, bacteriostats, antioxidants, preservatives, buffers, stabilizers, pH adjusters, osmolarity adjusters, antifoam and surfactants, and residues of antigen inactivating or fractionating agents, growth media and solvents commonly used in the production of medicines. Examples of these types of components can be found in the book The Handbook of Pharmaceutical Excipients (RAYMOND C. ROWE, Publisher The Pharmaceutical Press).
- compositions described in the present invention are available. The particular mode selected will depend on the particular active ingredient selected, the dosage required for therapeutic efficacy and the patient to whom the composition will be administered.
- the present invention describes the use of the compounds and compositions described herein for the treatment of cell proliferation-associated diseases such as acute lymphoid leukemia (ALL), tumors and inflammation.
- ALL acute lymphoid leukemia
- the present invention describes methods of treating cell proliferation-associated diseases such as acute lymphoid leukemia (ALL), tumors, and inflammation using the compounds and compositions described herein for the treatment of cell proliferation-associated diseases such as lymphoid leukemia. 0 acute (ALL), tumors and inflammation.
- ALL acute lymphoid leukemia
- ALL acute lymphoid leukemia
- Example 5 Effect of compounds on acute lymphoid leukemia (ALL) cell lines:
- IC 50 is defined as the concentration of a compound at which 50% of the maximum inhibition is obtained. After absorbance reading, survival curves were constructed and IC 50 values were obtained with the aid of GraphPad Prism software.
- HL60 leukemic cell line were treated with the 125 nM dose of compound 07 or with dimethylsulfoxide vehicle (DMSO) for 6h in DMEM medium supplemented with 10% fetal bovine serum. At the end of this period, cells were recovered by brief centrifugation and lysed in guanidine solution from the RNAspin Mini RNA Isolation (GE) kit.
- DMSO dimethylsulfoxide vehicle
- RNA Purification and Biotinylated Probe Preparation Total RNA was extracted from cells using the RNAspin Mini RNA Isolation (GE) kit following manufacturer's instructions. A total of 100 ng of RNA was used to prepare the biotinylated complementary RNA probe (Bio-cRNA) by cDNA synthesis followed by in vitro transcription amplification using the GeneChip WT cDNA Synthesis and Amplification Kit (Affymetrix) according to recommendations. from the manufacturer.
- GE RNAspin Mini RNA Isolation
- Oligonucleotide microarrays and hybridization arrays The cRNA probe of each replicate was hybridized to the human genome oligonucleotide microarray GeneChip Human Gene 1.0 ST Array (Affymetrix). Hybridization and subsequent washes and microarray development were performed following manufacturer's recommendations.
- GSEA Gene Set Expression Analysis
- Gene sets analyzed by GSEA were obtained from a number of public databases (BioCarta, Signaling Pathway Database, Signaling Gateway, Signal Transduction Knowledge Environment, Human Protein Reference Database, GenMAPP, KEGG, Gene Ontology, Sigma-Aldrich Pathways, Gene Arrays BioScience Corp., Human Cancer Genome Anatomy Consortium and NetAffx). The mean values of probe set expression for the same gene were considered, using 1000 permutations to define the False Discovery Rate (FDR) q-value. Gene sets with less than 5 and more than 500 components were not considered.
- FDR False Discovery Rate
- the mechanism of action of these drugs is the inhibition of tubulin and has recently been described as possible candidates for the treatment of leukemia (Spagnuolo PA, et al; The antihelmintic flubendazole inhibits microtubule. leukemia and myeloma Blood 2010; 1 15 (23): 4824-33) and solid tumors (Doudican N, et al; Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.
- Table 5a Compounds positively correlated with compound 07 by ATC code.
- Hsp90 is a chaperone that interacts and collocates with tubulin (Garnier C, et al; Heat-shock protein 90 (hsp90) in vitro binds to tubulin dimer and inhibits microtubule formation.
- Table 5b Compounds positively correlated with compound 07 by cell line. Rank Name CMap and Cell Line Average n Enrichment P Specificity% non-n
- Tubulin inhibitors can act in two ways: (1) by inhibiting tubulin polymerization or (2) by stabilizing tubulin to inhibit its depolymerization.
- GSEA analysis showed that compound 07 causes a dramatic decrease in expression of a set of tubulin-specific tubulin genes and chaperones ( Figure 1), which is typical of compounds that inhibit tubulin polymerization. Inhibition of tubulin polymerization results in free (unpolymerized) tubulin accumulation in the cell cytoplasm.
- Cytoplasmic free tubulin self-regulates negatively expression of tubulin mRNA, suppressing the formation of new tubulin mRNA and accelerating degradation of existing mRNA (Caron JM, et al; Autoregulation of tubulin synthesis in hepatocytes and fibroblasts. J Celi Biol 1985; 101 : 1763-72.). In contrast, compounds that stabilize tubulin filaments lead to increased tubulin expression.
- Example 7 Effect of compound 07 on cell cycle progression, cell cycle regulator activation and apoptosis induction:
- a) Cell cycle analysis assays Cells treated or not with compound 07 were fixed in 70% ethanol for 2 hours, washed in PBS and incubated for 15 min at 37 ° C in 1 ml Triton X-100 solution, 1%, 0.2 mg / mL RNAse and 20 pg / mL propidium iodide in PBS. Twenty thousand events were collected in a FACSCalibur flow cytometer, with red fluorescence quantification, excluding any cell aggregates by the width vs. width pattern. peak area of red fluorescence. Data deconvolution to obtain the percentage of cells in each phase of the cell cycle was performed using ModFit v2.0 software.
- Annexin V / PI labeled cell apoptosis quantitation assays Cells treated or not with compound 07 were washed in PBS and labeled by Annexin V Apoptosis Assay kit (Invitrogen). Briefly, cells were resuspended in suitable calcium-containing buffer and incubated for 15 min with Annexin V-FITC and 5 pg / mL propidium iodide. 10,000 events were collected in a FACSCalibur flow cytometer, excluding any debris by the forward vs. standard pattern. side scatter, with green and red fluorescence quantification.
- Results compatible with tubulin inhibition were obtained when analyzing the cell cycle of compound 07 treated Jurkat cells.
- Compound 07 treated Jurkat cells showed cell cycle arrest in G2 / M ( Figure 2).
- Bone marrow cells from healthy donors were cultured in semi-solid methylcellulose medium plus fetal bovine serum, bovine albumin serum, different growth factors (GM-CSF, G-CSF, SCF, IL-3, IL-6, Epo) and compound 07, whose action on hematopoiesis was evaluated. After two weeks of culture at 37 ° C and 5% CO 2 , the number of granulocyte (CFU-G), macrophage (CFU-), granulocyte / macrophage (CFU-GM), erythroid (BFU) colonies were counted. -E and CFU-E) and mixed colonies (CFU-GEMM).
- CFU-G granulocyte
- CFU- macrophage
- CFU-GM granulocyte / macrophage
- BFU erythroid
- Compound 07 was tested on healthy and mature phytohemagglutinin-stimulated T lymphocytes to evaluate its action against normal cells. As a positive control, colchicine was used. Results are presented in Table 6. Table 6. Survival percentage of phytohemagglutinin-stimulated healthy lymphocytes treated with different concentrations of compound 07.
- compound 07 was tested in a bone marrow cell colony formation assay grown in semi-solid methylcellulose medium plus growth factors. As shown in Table 7, compound 07, at a concentration very close to IC 50 (20 nM), exhibits inhibitory activity on erythrocyte formation comparable to a Pi3K pathway inhibitor used in the assay as a positive control. Compound 07 also has inhibitory activity against granulocytes and macrophages, but to a lesser extent compared to the ⁇ 3 ⁇ inhibitor. At a concentration of 200 nM, corresponding to 10 times the average IC 50 in ALL cells, compound 07 completely inhibited hematopoiesis.
- ALL acute lymphoid leukemia
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014125519A RU2664327C2 (ru) | 2011-11-25 | 2012-11-26 | Ацил-гидразоновые и оксадиазоловые соединения, фармацевтические композиции, содержащие их, и их применение |
CN201280063518.9A CN104159887A (zh) | 2011-11-25 | 2012-11-26 | 酰基-腙和噁二唑化合物、含有它们的药物组合物及其用途 |
KR1020147017498A KR102189562B1 (ko) | 2011-11-25 | 2012-11-26 | 아실-하이드라존 및 옥사디아졸 화합물, 이를 포함하는 약학 조성물 및 이의 용도 |
CA2869807A CA2869807C (en) | 2011-11-25 | 2012-11-26 | Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
JP2014542646A JP2015504432A (ja) | 2011-11-25 | 2012-11-26 | アシル−ヒドラゾンおよびオキサジアゾール化合物、これらを含有する医薬組成物およびその使用 |
US14/360,279 US20150191445A1 (en) | 2011-11-25 | 2012-11-26 | Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
BR112014012582A BR112014012582A2 (pt) | 2011-11-25 | 2012-11-26 | compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos |
EP12851308.2A EP2784061B1 (en) | 2011-11-25 | 2012-11-26 | Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI1107312-8 | 2011-11-25 | ||
BRPI1107312-8A BRPI1107312B1 (pt) | 2011-11-25 | 2011-11-25 | Composto de acil-hidrazona |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013075199A1 true WO2013075199A1 (pt) | 2013-05-30 |
Family
ID=48468927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2012/000480 WO2013075199A1 (pt) | 2011-11-25 | 2012-11-26 | "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150191445A1 (pt) |
EP (1) | EP2784061B1 (pt) |
JP (1) | JP2015504432A (pt) |
KR (1) | KR102189562B1 (pt) |
CN (1) | CN104159887A (pt) |
BR (2) | BRPI1107312B1 (pt) |
CA (1) | CA2869807C (pt) |
RU (1) | RU2664327C2 (pt) |
WO (1) | WO2013075199A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101719541B1 (ko) | 2015-08-13 | 2017-03-24 | 연세대학교 산학협력단 | 항암용 약학 조성물 및 ano1 활성억제제 |
KR20170141542A (ko) * | 2016-06-15 | 2017-12-26 | 국립암센터 | 위암을 예방 및 치료하는 rhoa 억제제의 약학적 조성물 |
CN110498809B (zh) * | 2018-05-17 | 2022-04-05 | 香港科技大学深圳研究院 | 基于酰腙配体类的有机硼化合物及其制备方法和应用 |
KR102131331B1 (ko) | 2018-09-19 | 2020-07-07 | 연세대학교 산학협력단 | 항암용 신규 약학 조성물 및 ano1 활성억제제 |
CN113336729B (zh) * | 2021-05-31 | 2022-05-27 | 四川大学华西医院 | 硝呋齐特类衍生物及其制备方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040138272A1 (en) | 2002-09-03 | 2004-07-15 | Mckerracher Lisa | 1,4-Substituted cyclohexane derivatives |
US20070066610A1 (en) | 2005-03-18 | 2007-03-22 | Kristi Leonard | Acylhydrazones as kinase modulators |
BRPI0418095A (pt) | 2003-12-23 | 2007-04-17 | Gpc Biotech Inc | inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos |
BRPI0508364A (pt) | 2004-03-02 | 2007-07-24 | Aventis Pharma Sa | derivados de 4-benzimidazol-2-ilpiridazin-3-ona |
US20080194562A1 (en) | 2005-01-21 | 2008-08-14 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60105621A (ja) * | 1983-11-14 | 1985-06-11 | Agency Of Ind Science & Technol | 細胞の分化誘導作用を有する生理活性物質およびその製法 |
IL94389A0 (en) * | 1989-06-01 | 1991-03-10 | Health Research Inc | Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and method of using same for diagnosis and treatment |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US6197806B1 (en) * | 1995-12-20 | 2001-03-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Eliminating agent for activated oxygen and free radicals |
CN1956984B (zh) * | 2004-04-01 | 2010-06-09 | 安万特药物公司 | 1,3,4-二唑-2-酮作为PPAR-δ调节剂 |
CN1824657A (zh) * | 2006-04-05 | 2006-08-30 | 贵州大学 | 3-取代-2-芳基取代-5-(3,4,5-三烷氧基苯基)-1,3,4-噁二唑衍生物及制备方法和用途 |
US20110189306A1 (en) * | 2010-01-13 | 2011-08-04 | Norbert Kartner | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES |
-
2011
- 2011-11-25 BR BRPI1107312-8A patent/BRPI1107312B1/pt active IP Right Grant
-
2012
- 2012-11-26 US US14/360,279 patent/US20150191445A1/en not_active Abandoned
- 2012-11-26 RU RU2014125519A patent/RU2664327C2/ru active
- 2012-11-26 EP EP12851308.2A patent/EP2784061B1/en active Active
- 2012-11-26 BR BR112014012582A patent/BR112014012582A2/pt not_active IP Right Cessation
- 2012-11-26 CN CN201280063518.9A patent/CN104159887A/zh active Pending
- 2012-11-26 JP JP2014542646A patent/JP2015504432A/ja active Pending
- 2012-11-26 CA CA2869807A patent/CA2869807C/en active Active
- 2012-11-26 KR KR1020147017498A patent/KR102189562B1/ko active IP Right Grant
- 2012-11-26 WO PCT/BR2012/000480 patent/WO2013075199A1/pt active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040138272A1 (en) | 2002-09-03 | 2004-07-15 | Mckerracher Lisa | 1,4-Substituted cyclohexane derivatives |
BRPI0418095A (pt) | 2003-12-23 | 2007-04-17 | Gpc Biotech Inc | inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos |
BRPI0508364A (pt) | 2004-03-02 | 2007-07-24 | Aventis Pharma Sa | derivados de 4-benzimidazol-2-ilpiridazin-3-ona |
US20080194562A1 (en) | 2005-01-21 | 2008-08-14 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
US20070066610A1 (en) | 2005-03-18 | 2007-03-22 | Kristi Leonard | Acylhydrazones as kinase modulators |
Non-Patent Citations (50)
Title |
---|
"The Handbook of Pharmaceutical Excipients", THE PHARMACEUTICAL PRESS |
BAIN, B.: "J. Diagn6stico em leucemias", 2003, ELSEVIER, pages: 01 - 56 |
BORCHHARDT, D.M. ET AL.: "Biochemical Evaluation of a Series of Synthetic Chalcone and Hydrazine Derivates as Novel Inhibitors of Cruzain from Trypanosoma cruzi", JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, vol. 21, no. 1, 2010, pages 142 - 150, XP055069491 * |
BORCHHARDT, DEISE M.; MASCARELLO, ALESSANDRA; CHIARADIA, LOUISE DOMENEGHINI; NUNES, RICARDO J.; OLIVA, GLAUCIUS; YUNES, ROSENDO A.: "Biochemical evaluation of a series of synthetic chalcone and hydrazide derivatives as novel inhibitors of cruzain from Trypanosoma cruzi", JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, vol. 21, no. 1, 2010, pages 142 - 150 |
C GARNIER: "Heat-shock protein 90 (hsp90) binds in vitro to tubulin dimer and inhibits microtubule formation", BIOCHEM BIOPHYS RES COMMUN, vol. 250, no. 2, 1998, pages 414 - 9 |
C STEVENS ET AL.: "Chk2 activates E2F-1 in response to DNA damage", NAT CELL BIOL, vol. 5, no. 5, 2003, pages 401 - 9, XP002309315, DOI: doi:10.1038/ncb974 |
CAO, X. ET AL.: "Synthesis and Biological Activity of a Series of Novel N-Substituted p-Lactams Derived from Natural Gallic Acid", JOURNAL OF THE CHINESE CHEMICAL SOCIETY, vol. 58, 2011, pages 35 - 40, XP055069493 * |
CARON JM ET AL.: "autoregulation of tubulin synthesis in hepatocytes and fibroblasts", CELL J BIOL, vol. 101, 1985, pages 1763 - 72 |
CHIDA, A. S.; VANL, P. V. S. N.; CHANDRASEKHARAM, M.; SRINIVASAN, R.; SINGH, A. K: "Synthesis of 2,3-dimethoxy-5-methyl-1,4-benzoquinone: a key fragment in coenzyme-Q series", SYNTHETIC COMMUNICATIONS, vol. 31, 2001, pages 657 - 660, XP001019402, DOI: doi:10.1081/SCC-100103252 |
CZAR MJ ET AL.: "Immunofluorescence localization of the 90-kDa heat-shock protein to cytoskeleton", EUR J CELL BIOL, vol. 70, no. 4, 1996, pages 322 - 30 |
DOUDICAN N ET AL.: "Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells", MOL CANCER RES, vol. 6, no. 8, 2008, pages 1308 - 315 |
DOWNING, JAMES R.; SHANNON, KEVIN M.: "Acute leukemia: A pediatric perspective", CANCER CELL, vol. 2, 2002, pages 437 - 445 |
F WEIS ET AL.: "The 90-kDa heat tubulin shock protein Hsp90 protects against thermal denaturation", J BIOL CHEM, vol. 285, no. 13, 2010, pages 9525 - 34 |
FALCK J ET AL.: "The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis", NATURE, vol. 410, no. 6830, 2001, pages 842 - 7 |
GOODMAN; GILMAN: "As bases farmacofogicas da terapeutica", 2006 |
GREAVES, M. F.: "Stem cell origins of leukaemia and curability", BRITISH JOURNAL OF CANCER, vol. 67, 1993, pages 413 - 423 |
GUIMARAES, C. R. W.; BOGER, D. L; JORGENSEN, W. L.: "Elucidation of Fatty Acid Amide Hydrolase Inhibition by Potent a-Ketoheterocycle Derivatives from Monte Carlo Simulations", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 127, 2005, pages 17377 - 17384 |
GUPTA K ET AL.: "antifungal antimitotic compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin", BIOCHEMISTRY, vol. 43, no. 21, 2004, pages 6645 - 6655 |
HERR, I.; DEBATIN, K. M.: "Cellular stress response and apoptosis in cancer therapy", BLOOD, vol. 98, 2001, pages 2603 - 2614, XP001145463, DOI: doi:10.1182/blood.V98.9.2603 |
HIRAO A: "DNA damage-induced activation of p53 by the checkpoint kinase Chk2", SCIENCE, vol. 287, no. 5459, 2000, pages 1824 - 7 |
JIN, L. ET AL.: "Synthesis, structure, and bioactivity of N'-substituted benzylidene- 3,4,5- trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-( 3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 5036 - 5040, XP005611690 * |
JIN, L.; CHEN, J.; SONG, B.; CHEN, Z.; YANG, S.; LI, Q.; HU, D.; XU, R., BIOORG MED CHEM, vol. 16, 2006, pages 5036 - 5040 |
KASPERS, G. J. ET AL.: "In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia", BLOOD, vol. 90, 1997, pages 2723, XP002363591 |
KASPERS, G. J.: "In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia", BLOOD, vol. 90, 1997, pages 2723, XP002363591 |
KUMAR, D.; SUNDAREE, S.; JOHNSON, E. 0.; SHAH, K.: "An efficient synthesis and biological study of novel indolyl-1,3,4- oxadiazoles as potent anticancer agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 4492 - 4494, XP026301732, DOI: doi:10.1016/j.bmcl.2009.03.172 |
LAKS, D.; LONGHI, F.; BEMARDES, W. M.; RAMOS, G. P. C., J PEDIATR, vol. 79, 2003, pages 149 - 158 |
LAMB, J.; CRAWFORD E.D.: "The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules", GENES AND DISEASE SCIENCE, vol. 313, 2006, pages 1929 - 1935, XP055253665, DOI: doi:10.1126/science.1132939 |
LEE JS ET AL.: "hCdsl-mediated phosphorylation of BRCA1 regulates the DNA damage response", NATURE, vol. 404, no. 6774, 2000, pages 201 - 4 |
LESZCZYNIECKA, M.; ROBERTS, T.; DENT, P.; GRANT, S.; FISHER, P. B.: "Differentiation therapy of human cancer: basic science and clinical applications", PHARMACOLOGY & THERAPEUTICS, vol. 90, 2001, pages 105 - 156 |
MATSUOKA S ET AL.: "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase", SCIENCE, vol. 282, no. 5395, 1998, pages 1893 - 7, XP002922301, DOI: doi:10.1126/science.282.5395.1893 |
MAZZONE, G.; ARRIGO REINA, R.: "3,4,5-Trimethoxybenzoyl hydrazides and their anti-MAO [monoamine oxidase] activity", BOLLETTINO DELLE SEDUTE DELLA ACCADEMIA GIOENIA DI SCIENZE NATURALI IN CATANIA, vol. 10, no. 8, 1971, pages 689 - 702 |
MAZZONE, G.; BONINA, F.; FORMICA, F.: "Some aroylhydrazones of halobenzaldehydes and halo-substituted 2,5-diaryl-1,3,4-oxadiazoles", FARMACO, EDIZIONE SCIENTIFICA, vol. 33, no. 12, 1978, pages 963 - 71 |
PIETERS, R. ET AL.: "In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions", BLOOD, vol. 76, 1990, pages 2327 - 2336 |
PIETERS, R. ET AL.: "Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia", LANCET, vol. 338, 1991, pages 399 - 403 |
PIETERS, R.: "In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions", BLOOD, vol. 76, 1990, pages 2327 - 2336 |
PLASSCHAERT, S.; VAN DER KOLK, D.; DE BONT, E.; VELLENGA, E.; KAMPS, W.; DE VRIES, E.: "Breast Cancer Resistance Protein (BCRP) in Acute Leukemia", LEUKEMIA & LYMPHOMA, vol. 45, 2004, pages 649 - 654 |
RANG, H. P.; DALE, M. M.; RITTER, J. M; MOORE, P. K.: "Farmacologia.", 2004, ELSEVIER, pages: 703 |
RANG, H. P; DALE, M. M.; RITTER, J. M; MOORE, P. K.: "Farmacologia", 2004, ELSEVIER, pages: 703 |
REDMOND T ET AL.: "Immunofluorescence colocalization of the 90-kDa heat-shock protein and microtubules in interphase and mitotic mammalian cells", EUR J CELI BIOI, vol. 50, no. 1, 1989, pages B6 - 75 |
ROBINSON, B.: "Fischer indole synthesis", CHEM. REV., vol. 4, 1963, pages 373 - 401 |
SAMUS, N. M.; TSAPKOV, V. I.; KURACHEVA, S. A.; BURDENKO, T. A.: "Synthesis and antimicrobial activity of coordination compounds of 3d-elements with some hydrazones derived by using 5-nitro-2-furaldehyde", KHIMLKO-FARMATSEVTICHESKII ZHURNAL, vol. 28, 1994, pages 41 - 44 |
SANCHEZ ER ET AL.: "Evidence that the 90-kilodalton heat shock protein is associated with tubulin-containing complexes in L cell cytosol and in intact PtK cells", MOL ENDOCRINOL, vol. 2, no. 8, 1988, pages 756 - 60 |
SPAGNUOLO PA ET AL.: "The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma", BLOOD, vol. 115, no. 23, 2010, pages 4824 - 33 |
TROEBERG, L.; CHEN, X.; FLAHERTY, T. M.; MORTY, R. E.; CHENG, M.; HUA, H.; SPRINGER, C.; MCKERROW, J. H.; KENYON, G. L.; LONSDALE-: "Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei", MOLECULAR MEDICINE, vol. 6, 2000, pages 660 - 669 |
VIGORITA, M. G.; OTTANA, R; ZAPPALA, C.; MACCARI, R.; PIZZIMENTI, F. C.; GABBRIELLI, G.: "Halogenated isoniazid derivatives as possible antimycobacterial and anti-HIV agents - 111", FARMACO, vol. 49, 1994, pages 775 - 781 |
VIGORITO E ET AL.: "Contributions of p53 and PMA to gamma-irradiation induced apoptosis in Jurkat cells", HEMATOL CELL THER, vol. 41, no. 4, 1999, pages 153 - 61, XP019372038 |
WANG, Z. ET AL.: "Identifying Novel Molecular Structures for Advanced Melanoma by Ligant-Based Virtual Screening", JOURNAL OF CHEMICAL INFORMATION AND MODELING, vol. 49, 2009, pages 1420 - 1427, XP009170439 * |
WANG, Z.; LU, Y.; SEIBEL, W.; MILLER, D. D.; LI, W.: "Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening", JOURNAL OF CHEMICAL INFORMATION AND MODELING, vol. 49, 2009, pages 1420 - 1427, XP009170439, DOI: doi:10.1021/ci800445a |
WANI, M. C.; TAYLOR, H. L.; WALL, M. E.; COGGON, P.; MCPHAIL, A. T.: "Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 93, 1971, pages 2325 - 2327, XP002037887, DOI: doi:10.1021/ja00738a045 |
WORLD CANCER REPORT 2008, 23 February 2011 (2011-02-23), Retrieved from the Internet <URL:http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php> |
Also Published As
Publication number | Publication date |
---|---|
RU2014125519A (ru) | 2015-12-27 |
CN104159887A (zh) | 2014-11-19 |
EP2784061A1 (en) | 2014-10-01 |
EP2784061B1 (en) | 2018-11-07 |
CA2869807C (en) | 2021-03-09 |
US20150191445A1 (en) | 2015-07-09 |
KR20140112489A (ko) | 2014-09-23 |
JP2015504432A (ja) | 2015-02-12 |
EP2784061A4 (en) | 2015-05-27 |
RU2664327C2 (ru) | 2018-08-16 |
BRPI1107312A2 (pt) | 2016-09-20 |
KR102189562B1 (ko) | 2020-12-14 |
CA2869807A1 (en) | 2013-05-30 |
BRPI1107312B1 (pt) | 2021-09-08 |
BR112014012582A2 (pt) | 2017-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4989976B2 (ja) | 翻訳開始阻害剤としての3−3−二置換オキシインドール | |
WO2013075199A1 (pt) | "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos | |
WO2016155545A1 (zh) | 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用 | |
WO2014124384A1 (en) | Compositions and methods for cancer therapy | |
JP5649652B2 (ja) | 置換ヒドラジド類化合物及びその応用 | |
JP2023524563A (ja) | Apol1-関連疾患の治療に使用するための組成物 | |
CN103502219A (zh) | 作为治疗剂的新型小分子 | |
WO2014127722A1 (zh) | 氮杂环取代二氢青蒿素衍生物及其应用 | |
EP3252039B1 (en) | Compound containing indoleacetic acid core structure and use thereof | |
US20210309630A1 (en) | Allosteric inhibitor of wee1 kinase | |
Song et al. | Discovery of bazedoxifene analogues targeting glycoprotein 130 | |
US9688651B2 (en) | Geranyl geranyl acetone analogs and uses thereof | |
ES2550959T3 (es) | Compuestos antineoplásicos y composiciones farmacéuticas de los mismos | |
WO2021087077A1 (en) | Small molecule inhibitors of autophagy and histone deactylases and uses thereof | |
JP5717129B2 (ja) | ウィザノライド成分を組み合わせた抗癌剤 | |
BR122023026497A2 (pt) | Uso de um composto e método para produzir um composto | |
WO2007062030A2 (en) | Quinuclidinone derivatives as anticancer agents | |
JP5986098B2 (ja) | インテグリン結合キナーゼ阻害剤 | |
CN111153817B (zh) | 苯氧基-n-苯基苯胺衍生物及其应用 | |
WO2024000615A1 (zh) | 一种酪氨酸蛋白激酶抑制剂及其用途 | |
JP7138975B2 (ja) | 新生物障害及び神経性障害の診断、治療及び予防のための組成物及び方法 | |
WO2004039797A1 (fr) | Composes d'indole de type special, leur preparation et leur utilisation pour le traitement et la prevention de maladies telles que le cancer | |
Li et al. | Synthesis, biological activity evaluation and mechanism of action of novel bis-isatin derivatives as potential anti-liver cancer agents | |
CN117447480A (zh) | E20在化疗致卵巢损伤保护中的应用 | |
JP2024509267A (ja) | リボソーム障害に関連する貧血を処置するための組成物および方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12851308 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2014542646 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012851308 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014125519 Country of ref document: RU Kind code of ref document: A Ref document number: 20147017498 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2869807 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014012582 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14360279 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112014012582 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140523 |